Unknown

Dataset Information

0

A Case of Treatment Resistance and Complications in a Patient with Stiff Person Syndrome and Cerebellar Ataxia.


ABSTRACT: Background:Antibodies against glutamic acid decarboxylase (GAD) are associated with Stiff Person Syndrome (SPS). Case report:A 50-year-old woman presented with symptoms progressed over 9 years, resulting in a cerebellar ataxia and right upper limb tremor. Investigations revealed elevated serum and CSF anti-GAD antibody titres (98.6 and 53.4 ?/ml, respectively). Treatment included intravenous immunoglobulin and immunomodulation (infliximab and rituximab), improving her stiffness, but with no impact on the ataxia-related symptoms. Subsequent high-dose steroids led to diabetic ketoacidosis and unmasking of an insulin-dependent diabetes mellitus. Discussion:This case illustrates several key features: (1) the combined clinical picture of SPS and cerebellar ataxia is a rare phenotype associated with anti-GAD antibodies; (2) the cerebellar ataxia described was progressive and poorly responsive to immunomodulatory therapy; and (3) the potential for development of further autoimmune sequelae in response to immunosuppression, namely, the development of insulin-dependent diabetes in response to treatment with high-dose oral steroids.

SUBMITTER: Jones LA 

PROVIDER: S-EPMC6778423 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Case of Treatment Resistance and Complications in a Patient with Stiff Person Syndrome and Cerebellar Ataxia.

Jones Lliwen A LA   Baber Waqaar W   Wardle Mark M   Robertson Neil P NP   Morris Huw R HR   Church Alistair A   Llewelyn John G JG   Peall Kathryn J KJ  

Tremor and other hyperkinetic movements (New York, N.Y.) 20191001


<h4>Background</h4>Antibodies against glutamic acid decarboxylase (GAD) are associated with Stiff Person Syndrome (SPS).<h4>Case report</h4>A 50-year-old woman presented with symptoms progressed over 9 years, resulting in a cerebellar ataxia and right upper limb tremor. Investigations revealed elevated serum and CSF anti-GAD antibody titres (98.6 and 53.4 μ/ml, respectively). Treatment included intravenous immunoglobulin and immunomodulation (infliximab and rituximab), improving her stiffness, b  ...[more]

Similar Datasets

| S-EPMC5417285 | biostudies-literature
| S-EPMC6353533 | biostudies-literature
| S-EPMC3383307 | biostudies-literature
| S-EPMC8304346 | biostudies-literature
| S-EPMC7492528 | biostudies-literature
| S-EPMC6800926 | biostudies-literature
| S-EPMC3035624 | biostudies-literature
| S-EPMC10582361 | biostudies-literature
| S-EPMC5524563 | biostudies-other
| S-EPMC7772861 | biostudies-literature